24.6 C
Vientiane
Saturday, June 21, 2025
spot_img
Home Blog Page 518

Saramonic K9 Unveiled – Digital UHF Audio System With User Experience Friendlier for Filmmakers

NEW YORK, April 7, 2025 /PRNewswire/ — Saramonic launches Saramonic K9, its first dual-channel digital UHF wireless audio system for filmmakers during NAB Show 2025. This new system features what a professional looks for in a reliable audio system: ultra-wide 550-960 MHz digital UHF, 130 dB high dynamic range, 32-bit float onboard recording*, and timecode, giving filmmakers a friendlier user experience.

A Closer Look of Saramonic K9
A Closer Look of Saramonic K9

Cinema-Grade Precision And Reliability Redefined

Strong anti-interference performance, high-fidelity audio recordings, and safety backup constitute a reliable audio system. Designed with that in mind, Saramonic K9 is a digital UHF system that converts audio signals into a digital format before transmission, making it less prone to interference than analog. In addition, the ultra-wide UHF spectrum (550-960 MHz) it operates in offers more channels to auto-scan and locks onto optimal channels within 0.3 seconds, even in densely crowded RF environments.

The Saramonic K9 delivers cinematic clarity through its 130dB input – 120dB output dynamic range , capturing whispers to explosions without distortion. Engineered with industry-standard 32-bit float recording, Saramonic K9 preserves 192kHz/32bit fidelity across its full dynamic spectrum. Editors gain post-production superpowers: rescuing clipped dialogue, amplifying subtle ambiance, or isolating frequencies – all while maintaining phase accuracy.

Cinema-Ready Innovation for All Productions

  • 32-Bit Float Onboard Recording with 32GB storage safeguards pristine audio for post-production freedom, capturing whispers to explosions without clipping.
  • Timecode Sync ensures frame-perfect alignment across multi-camera shoots, slashing editing time.
  • Saramonic System controls up to 48 devices remotely, offering more flexibility when transmitters are hard to access.
  • Industry’s Smallest IP67 Lavalier Mic (Ø3mm) withstands dust, sweat, and rain while remaining virtually invisible on talent.
  • Dual-Screen Monitoring displays real-time transmitter status and RF health at a glance.

Availability

Saramonic K9 is available through Saramonic Online Store and worldwide dealers with a recommended retail price at EUR 999 (global version) and USD 999.99 (US version). Order now: saramonic.com/product/saramonic-k9-uhf-microphone

About Saramonic

Saramonic is a leading audio brand dedicated to empowering creators to sound remarkable. Founded in 2012, the company has built a strong foundation for innovation, which is supported by an R&D team of over 100 members, 400+ patents, and 5 acoustic labs. Today, Saramonic continues to drive innovation for its growing community of 40 million users.

Contact: Jingyi Chen, chenjinyi@sz-cf.cn

Agoda Highlights Top Markets Traveling to Thailand for Songkran 2025

SINGAPORE, April 7, 2025 /PRNewswire/ — Digital travel platform Agoda reveals the top international markets exploring traveling to Thailand for Songkran this year, with Malaysia leading the list. Based on accommodation searches made on Agoda, Malaysian travelers are followed by visitors from Hong Kong SAR, Indonesia, South Korea, and the Philippines when it comes to their eagerness to take part in the Thai New Year celebrations.

Songkran, celebrated annually from April 13-15, is famous for its spectacular water fights that take place across Thailand. The top five city destinations for international Songkran visitors are Bangkok, Pattaya, Phuket, Hat Yai, and Chiang Mai.

Key events in Bangkok include the Maha Songkran World Water Festival 2025, hosted by the Tourism Authority of Thailand (TAT), and the Siam Songkran Music Festival, featuring performances by renowned artists from around the globe.

Akaporn Rodkong, Country Director Thailand at Agoda, shared, “As the Songkran festival approaches, it’s exciting to see a wide range of international tourists considering visiting Thailand. And rightly so—Thailand’s lively celebrations and unique experiences create an atmosphere that’s hard to resist. Whether celebrating Songkran in Bangkok or exploring other destinations in Thailand, Agoda is here to help travelers find the best deals on flights, accommodations, and activities to make this festive season unforgettable.”

To make Songkran even more exciting and affordable, Agoda is offering a “Songkran Fest” promotion, providing travelers with up to 10% additional discounts at participating hotels in Thailand. The promotion is available for bookings and stays made before April 15, 2025. For more information, visit https://www.agoda.com/SongkranFestTH.

Hurom Wins Patent Infringement Case Against NUC (Kuvings) in European Unified Patent Court

Court Bans NUC Juicer Sales in Europe, Orders Compensation, Recall, and Destruction of Infringing Products

SEOUL, South Korea, April 7, 2025 /PRNewswire/ — Hurom, the global pioneer in slow juicing and the inventor of the world’s first vertical juicer, has secured a major legal victory against NUC, maker of the Kuvings juicer line, in the Unified Patent Court (UPC) of Europe.

On March 11, the UPC’s regional division in Mannheim, Germany ruled that NUC—including its Korean headquarters, European subsidiary, and distributor Warmcook—had infringed Hurom’s European patent (EP2028981).

As a result, NUC is now banned from selling its juicers in Europe, with any violations subject to a fine of €2,000 per infringing unit sold.

The court also ordered NUC to compensate Hurom for damages and cover all litigation costs, as well as recall and destroy all infringing products already distributed in the market. One of the key products found to be in violation is the Kuvings AUTO10 juicer.

This ruling follows Hurom’s previous legal wins in South Korea and the United States, further reinforcing its position as the original innovator behind vertical juicing technology.

In December 2024, the Korea Trade Commission determined that NUC had infringed Hurom’s patents and engaged in unfair trade practices, issuing a corrective order and imposing a fine. Similarly, in July 2024, Amazon’s Amazon Patent Evaluation Express (APEX) process (APEX ID: 15060613361) confirmed NUC’s patent infringement, resulting in the suspension of several key Kuvings juicer models in the U.S. market.  

Hurom CEO Jaewon Kim commented, “This ruling is a strong affirmation of Hurom’s technological leadership on the global stage,” and added, “We will continue to take firm action against reckless patent infringement and low-cost knockoffs that compromise our mission of promoting health through fruit and vegetable consumption.”

*Unified Patent Court (Germany) Case Numbers: PR_ACT_17336/2024, PR_ACT_17365/2024

DPC Dash – Domino’s Pizza China Shows Growth Momentum, While Building Resilient Community in the First Quarter of 2025

HONG KONG, April 7, 2025 /PRNewswire/ — DPC Dash – Domino’s Pizza China (“DPC Dash” or the “Company”) (1405.HK), Domino’s Pizza’s exclusive master franchisee in the China Mainland, the Hong Kong Special Administrative Region of China, and the Macau Special Administrative Region of China, continued to demonstrate growth momentum in the first quarter of 2025, while building a resilient community through its proven 4D strategy of Development, Delicious Pizza at Value, Delivery, and Digital, further consolidating its industry-leading position.

According to Frost & Sullivan, DPC Dash ranked second in pizza sales nationwide in 2024. The Chinese mainland market ranks as the third-largest Domino’s Pizza international market by store count as of December 31, 2024. In the first quarter of 2025, DPC Dash continued to strengthen its market share, demonstrating significant benefits from its penetration strategy. As reported in the First Quarter 2025 Investor Fact Sheet (“investor fact sheet”), DPC Dash operated 1,105 stores in 45 cities across mainland China as of March 31, 2025.

DPC Dash continues to adopt the “go-deeper, go-broader” store network strategy, maintaining a healthy and rapid growth of its store network. At the start of 2025, DPC Dash entered six new cities, accelerating its penetration into lower-tier cities. Along with the expansion in new store numbers, DPC Dash has further established a global sales benchmark. The same-store sales growth (SSSG) in first quarter of 2025 remained positive and marked the 31st consecutive quarter of positive SSSG since the current management took over in the third quarter of 2017. As of the first quarter of 2025, DPC Dash holds all 40 top positions in Domino’s global system for first 30-day sales, proving its brand appeal and operational capability in mainland Chinese cities. On March 3, 2025, DPC Dash received the Gold Franny Award from Domino’s Pizza, Inc. for the seventh consecutive year. This award recognizes U.S. and international franchisees within the Domino’s global system for outstanding operating results, store development, and growth.

As of March 31, 2025, the number of net new stores opened, stores currently under construction, and stores that have signed for DPC Dash has reached nearly 61% of the total targeted store opening plan for the full year, with 97 new stores opened in the first quarter, steadily advancing its high-quality expansion plan.

With this growth, DPC Dash is building a resilient community, with 27.2 million loyalty program members as of March 31, 2025. Over the past 12 months, 12.6 million new customers placed their first orders with Domino’s Pizza China. DPC Dash continues to leverage its digital initiatives to drive customer engagement and attract a large number of new customers through multiple online channels, while also enhancing its capability to offer personalized rewards, effectively improving new customer conversion and existing customer retention.

In the first quarter of 2025, DPC Dash continued to activate consumer demand through product and marketing innovations. The company launched several new products and limited-time promotions, including Singapore Style Sausage & Chicken Pizza, American Style Beef Bacon Pineapple Pizza, Avocado Double Decker, and snacks, alongside a limited-time free crust upgrade promotion with terms and conditions apply. During the Lunar New Year, the company partnered with the popular NetEase-developed video game Egg Party for a co-branded marketing campaign and introduced its signature “Mega Week (BOGO)” promotion at the end of the quarter, further boosting consumer interest.

Meanwhile, DPC Dash actively builds an ideal workplace for employees, leading transformation, inspiring potential, and accelerating overall achievement. In the first quarter of 2025, DPC Dash was recognized as a 2024 Best Employer by Mercer for its exceptional performance in employee engagement, agility, engaging leadership and talent focus, marking the third consecutive year that the Company has received this prestigious award.

Looking ahead, DPC Dash will remain committed to offering delicious pizza at value, enhancing dining and consumption experiences, and creating sustainable long-term value for consumers, investors, employees, and other stakeholders.

About DPC Dash Ltd

DPC Dash is Domino’s Pizza’s exclusive master franchisee in the Chinese mainland, the Hong Kong Special Administrative Region of China and the Macau Special Administrative Region of China. Domino’s Pizza, Inc., DPC Dash’s global franchisor, is one of the most widely-recognized global consumer brands and the world’s largest pizza company. Led by a seasoned and visionary management team, DPC Dash is a market leader that differentiates from competitors with, among others, a continually innovated and localized pizza-focused menu, unique expertise and leadership in delivery, technology focus and scalable and replicable store economic model. DPC Dash operates 1,105 stores in 45 cities in the Chinese mainland as of March 31, 2025.

For more information, please visit www.dpcdash.com 

For official company announcements, please visit www.hkexnews.hk 

Contacts

DPC Dash Ltd Investor Relations:
DPC Dash Ltd
IR@dominos.com.cn 

ICR, LLC
dpcdashIR@icrinc.com 

DPC Dash Ltd Media Relations:
ICR, LLC
dpcdashPR@icrinc.com 

George Clinical Rebrands as Emerald Clinical Trials

New name reflects company’s growth and vision to help bring certainty and transparency to global clinical trials

SINGAPORE, April 7, 2025 /PRNewswire/ — George Clinical, a leading clinical research organization (CRO) operating worldwide, is pleased to announce it has rebranded to become Emerald Clinical Trials. This strategic name change underscores the company’s well-established position as a dedicated, reliable, consistent, and flexible CRO, while mitigating global clinical development risks through deep therapeutic and local expertise cultivated over 20 years.

Emerald Clinical Trials continues to focus on end-to-end services across all therapeutic areas designed to change lives⁠ while ⁠advancing innovations that help evolve global clinical research practices. With its strong track record in Oncology and Cardio-Renal-Metabolic (CRM) therapeutic areas, trusted expertise in Asia Pacific, and global scientific leadership, Emerald Clinical Trials is a highly differentiated clinical CRO on the world stage. The company’s extensive reach operating directly in 42 countries and in 70 countries through partnerships ensures seamless execution of clinical trials worldwide.

The new brand amplifies the exceptional work of Emerald Clinical Trials and highlights the breadth and depth of its experience to an even broader audience. It emphasizes a strong commitment to patients, customers, and partners.

The company’s deep commitment to customer-centricity fosters long-term relationships built on trust, reliability, and measurable success. Emerald’s ability to deliver predictability in clinical trials is underscored by a track record of repeat business, industry excellence awards, and consistent performance in bringing therapies to market.

“For the past two decades, Emerald Clinical Trials has been focused on delivering high quality trials that combine a global reach with a high-touch approach. We offer the footprint and expertise of a large CRO with the personalized attention and flexibility of a smaller partner, ensuring that every client, from emerging biotech to top-tier pharma, receives the focused, hands-on support they need to de-risk their clinical programs,” said Mary Gunn, CEO, Emerald Clinical Trials. “This exciting transformation strengthens our position as a trusted partner in clinical trials, while reaffirming our commitment to our clients and core values.”

“We decided early on that we wanted to work with a CRO that has a flexible approach, and solutions tailored to the specific needs of each trial, whether accelerating timelines, adapting to evolving study requirements, or scaling resources efficiently,” said Dr. Daniel Tillett, CEO, Race Oncology, an Emerald client. “Agility is critical for biopharma companies that require a partner who can pivot alongside them, rather than slow them down with bureaucratic inefficiencies, and that is truly a strength of Emerald Clinical Trials.”

About Emerald Clinical Trials
Emerald Clinical Trials is a leading clinical research organization operating worldwide that serves over 100 biotechs, and 6 of the top 10 pharmaceutical companies. Headquartered in Singapore and driven by operational expertise and scientific excellence, the company provides comprehensive clinical trial services to clients globally, offering solutions across all trial phases. For more information, visit www.emeraldclinical.com.

Media Contact: Shannon Severino, shannon@severinocommunications.com, T +1 412 608 2393

 

Luye Pharma Announces U.S. Launch of ERZOFRI® (paliperidone palmitate) Extended-Release Injectable Suspension for the Treatment of Schizophrenia and Schizoaffective Disorder

PRINCETON, N.J., April 7, 2025 /PRNewswire/ — Luye Pharma Group today announced that ERZOFRI® (paliperidone palmitate) extended-release injectable suspension is now available for commercial sale in the U.S. for the treatment of adults with schizophrenia and as a monotherapy or adjunct therapy for the treatment of adults with schizoaffective disorder.

ERZOFRI, administered once a month, delivers the active ingredient, paliperidone, through a long-acting, extended-release delivery system. It simplifies treatment by enabling single-dose initiation due to its unique 351 mg initiation dose. The currently prescribed monthly paliperidone palmitate long-acting injectable (LAI) requires two initiation doses, on Day 1 and Day 8.

ERZOFRI may cause serious side effects, including:
Increased risk of death in elderly people with dementia-related psychosis. ERZOFRI increases the risk of death in elderly people who have lost touch with reality (psychosis) due to confusion and memory loss (dementia). ERZOFRI is not for the treatment of people with dementia-related psychosis. The most common side effects of ERZOFRI include injection site reactions, sleepiness or drowsiness, dizziness, feeling restless or like you need to move, and abnormal muscle movements including tremor (shaking), shuffling, uncontrolled involuntary movements, and abnormal movements of your eyes.

Both schizophrenia and schizoaffective disorder are severe, chronic psychiatric disorders characterized by recurrent relapses[1]. Non-adherence to medication is a major challenge in patients with such conditions. Failure of follow-up care after discharge significantly increases patients’ non-adherence to prescribed medications, relapse and rehospitalization[2]. LAI antipsychotics, with a reduced dosage frequency compared to oral antipsychotics, effectively improve medication adherence and reduce the risk of healthcare providers not knowing if their patients fail to follow the prescribed dosage regimen[3].

ERZOFRI’s approval by the FDA is based on the results of an open-label, randomized, multiple-dose, parallel-group study evaluating its pharmacokinetic (PK) profile and relative bioavailability at steady state versus an established paliperidone palmitate LAI drug for reference. The study demonstrated the bioequivalence of ERZOFRI to the listed drug at steady state (treatment day 8) without the need for a second initiation injection.

Comparable total drug exposure and a safety profile consistent with the listed drug were established. In addition to the unique 351 mg/2.25mL initiation dose, ERZOFRI is available in single-use kits in the following strengths: 39 mg/0.25mL, 78 mg/0.5 mL, 117 mg/0.75 mL, 156 mg/mL, and 234 mg/1.5 mL.

“This newly approved long-acting injectable antipsychotic for the management of schizophrenia can help address treatment initiation complexities and provides an exciting alternative to help patients reach their treatment goals.” said Christoph U Correll, MD, Professor of Psychiatry, Zucker School of Medicine at Hofstra/Northwell, New York, USA.

Rongbing Yang, President of Luye Pharma Group, added: “Medication adherence and discontinuation present a major challenge in the treatment of schizophrenia and schizoaffective disorder. Using LAIs is effective in increasing medication adherence. ERZOFRI, with its simplified dosage regimen eliminating the need for a second dose when initiating treatment is expected to increase treatment adherence in the initial stage. Its commercial launch in the U.S. marks a major milestone in our commitment to addressing the unmet medical needs of patients in the U.S. The central nervous system is a key therapeutic area of focus for Luye Pharma, and we are committed to providing innovative therapies to combat mental disorders and expand treatment options.”

 

ERZOFRI® (paliperidone palmitate) extended-release injectable suspension
INDICATIONS

What is ERZOFRI® (paliperidone palmitate)?

ERZOFRI is a prescription medicine given by injection by a healthcare provider and used to treat:

  • schizophrenia in adults
  • schizoaffective disorder in adults either alone or with other medicines such as mood stabilizers or antidepressants

It is not known if ERZOFRI is safe and effective in children.

 

IMPORTANT SAFETY INFORMATION FOR ERZOFRI (paliperidone palmitate)
ERZOFRI may cause serious side effects, including:
Increased risk of death in elderly people with dementia-related psychosis. ERZOFRI increases the risk of death in elderly people who have lost touch with reality (psychosis) due to confusion and memory loss (dementia). ERZOFRI is not for the treatment of people with dementia-related psychosis.

Do not receive ERZOFRI if you are allergic to paliperidone, risperidone, or any of the ingredients in ERZOFRI.

What are the possible serious side effects of ERZOFRI?

Cardiovascular problems (including stroke) in elderly people with dementia-related psychosis that can lead to death.

Neuroleptic Malignant Syndrome (NMS) a serious condition that can lead to death. Call your healthcare provider right away or go to your nearest emergency room right away if you get any of the following signs or symptoms:

  • high fever
  • stiff muscles
  • confusion
  • sweating
  • changes in your breathing, pulse, heart rate, or blood pressure

Problems with your heartbeat. These heart problems can cause death. Call your healthcare provider right away if you get any of these symptoms:

  • passing out or feeling like you will pass out
  • dizziness
  • feeling as if your heart is pounding or missing beats

Uncontrolled body movements (tardive dyskinesia). ERZOFRI may cause movements that you cannot control in your face, tongue, or other body parts. Tardive dyskinesia may not go away, even if you stop taking ERZOFRI. Tardive dyskinesia may also start after you stop taking ERZOFRI.

Problems with your metabolism such as:

  • High blood sugar (hyperglycemia) and diabetes. Increases in blood sugar can happen in some people who are treated with ERZOFRI. Extremely high blood sugar can lead to coma or death. If you have diabetes or risk factors for diabetes such as being overweight, or a family history of diabetes, your healthcare provider should check your blood sugar before you start treatment and during your treatment with ERZOFRI.

    Call your healthcare provider if you get any of these symptoms of high blood sugar during treatment with ERZOFRI:
    • feel very thirsty
    • feel very hungry
    • feel sick to your stomach
    • need to urinate more than usual
    • feel weak or tired
    • feel confused, or your breath smells fruity
  • Increased fat levels (cholesterol and triglycerides in your blood). Your healthcare provider may check your cholesterol and triglyceride levels during treatment with ERZOFRI.
  • Weight gain. You and your healthcare provider should check your weight regularly during treatment with ERZOFRI.

Decreased blood pressure (orthostatic hypotension) and fainting. You may feel lightheaded or faint when you rise too quickly from a sitting or lying position.

Falls. ERZOFRI may make you sleepy or dizzy, may cause a decrease in your blood pressure when changing position (orthostatic hypotension), and can slow your thinking and motor skills which may lead to falls that can cause fractures or other injuries.

Low white blood cell counts. Your healthcare provider may do blood tests during treatment with ERZOFRI.

Increased prolactin levels in your blood (hyperprolactinemia). ERZOFRI may cause a rise in the blood levels of a hormone called prolactin that may cause side effects including missed menstrual periods, a reversible reduction in fertility in females who are able to become pregnant, leakage of milk from the breasts, development of breasts in men, or problems with erection.

Sleepiness, drowsiness feeling tired, difficulty thinking and doing normal activities.

Seizures (convulsions).

Difficulty swallowing that can cause food or liquid to get into your lungs.

Prolonged or painful erection lasting more than 4 hours (priapism). Call your healthcare provider or go to your nearest emergency room right away if you have an erection that lasts more than 4 hours.

Problems with control of your body temperature so that you feel too warm.

 

Before taking ERZOFRI, tell your healthcare provider about all of your medical conditions including if you:

  • have never taken paliperidone or risperidone before
  • have had neuroleptic malignant syndrome (NMS)
  • have or had heart problems, including heart attack, heart failure, abnormal heart rhythm, or long QT syndrome
  • have or had low levels of potassium or magnesium in your blood
  • have or had uncontrolled movements of your tongue, face, mouth or jaw (tardive dyskinesia)
  • have or had kidney or liver problems
  • have or had high blood sugar, diabetes or have a family history of diabetes
  • have or had high levels of total cholesterol, LDL cholesterol, or triglycerides, or low levels of HDL cholesterol
  • have Parkinson’s disease or a type of dementia called Lewy Body Dementia
  • have or had problems with dizziness or fainting or are being treated for high blood pressure
  • have or had a low white blood cell count
  • have or had seizures or epilepsy
  • are pregnant or plan to become pregnant. It is not known if ERZOFRI will harm your unborn baby.
    • If you become pregnant during treatment with ERZOFRI, talk to your healthcare provider about registering with the National Pregnancy Registry for Atypical Antipsychotics. You can register by calling 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/.
    • Babies born to women who are treated with ERZOFRI during their third trimester of pregnancy may experience symptoms such as tremors, irritability, excessive sleepiness, eye twitching, muscle spasms, decreased appetite, difficulty breathing, or abnormal movement of arms and legs. Let your healthcare provider know if these symptoms occur.
  • are breastfeeding or plan to breastfeed. ERZOFRI can pass into your breastmilk.
    • Talk to your healthcare provider about the best way to feed your baby if you receive ERZOFRI.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. ERZOFRI and certain other medicines may affect each other causing possible serious side effects or affect the way each other works. Know the medicines you take. Keep a list of them to show to your healthcare provider or pharmacist when you get a new medicine.

 

The most common side effects of ERZOFRI include:

  • injection site reactions
  • sleepiness or drowsiness
  • dizziness
  • feeling restless or like you need to move
  • abnormal muscle movements including tremor (shaking), shuffling, uncontrolled involuntary movements, and abnormal movements of your eyes

Tell your healthcare provider if you have any side effect that bothers you or does not go away. These are not all of the possible side effects of ERZOFRI. Call your doctor for medical advice about side effects. You may report side effects to FDA at www.fda.gov/medwatch or call 1-800- FDA-1088.

 

About Luye Pharma Group

Luye Pharma Group is an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications. The company has established R&D centers in China, the U.S. and Europe, with a robust pipeline of over 20 drug candidates in China and more than 10 drug candidates in other international markets. Luye Pharma maintains high-level international standards in novel drug delivery technologies including microspheres, liposomes, and transdermal drug delivery systems. The company has achieved multiple innovations in new chemical entities and antibodies, and is also actively making strategic developments in the fields of cell therapies and gene therapies.

Luye Pharma is developing a global supply chain of 8 manufacturing sites built up around the world, with GMP quality management and control systems established in line with international standards. With more than 30 products covering the central nervous system, oncology, cardiovascular, metabolism and other therapeutic areas, business is conducted in over 80 countries and regions around the world, including the largest pharmaceutical markets — China, the U.S., Europe and Japan, as well as in fast-growing emerging markets.

[1]. Anne Rivelli, Veronica Fitzpatrick, Michael Nelson, et al. Real-world predictors of relapse in patients with schizophrenia and schizoaffective disorder in a large health system. Schizophrenia (Heidelb) (2024). DOI: 10.1038/s41537-024-00448-2.

[2]. Lee SY, et al. Outpatient Follow-Up Visit after Hospital Discharge Lowers Risk of Rehospitalization in Patients with Schizophrenia: A Nationwide Population-Based Study. Psychiatry Investig. 2015;12(4):425-33. DOI: 10.4306/pi.2015.12.4.425

[3]. Carmela Benson, et al. Treatment patterns and hospitalizations following rejection, reversal, or payment of the initial once-monthly paliperidone palmitate long-acting injectable antipsychotic claim among patients with schizophrenia or schizoaffective disorder. J Manag Care Spec Pharm. 2024 Jun 3:1-13. DOI: 10.18553/jmcp.2024.23252.

US-ERZ-PM-250300020-v1.0-03/2025

 

 

Huatai Securities Shares FinTech Practices with Hong Kong SFC


HONG KONG SAR – Media OutReach Newswire – 7 April 2025 – ​Huatai Securities recently hosted a FinTech knowledge-sharing session with the Hong Kong Securities and Futures Commission (SFC). The event aimed to share forward-looking perspectives on financial technology and contribute to shaping the future of financial services in an increasingly AI-driven landscape.

The session covered financial-specific large language models, intelligent credit research, and innovations in the fixed income, currencies, and commodities (FICC) trading platform. Drawing on its own expertise, the company shared its latest progress in infrastructure and platform development, along with its efforts to integrate artificial intelligence into financial applications, on which the company has placed strong emphasis in recent years.

During the session, the company’s technical experts reviewed AI large language model developments globally and in China. The company presented its system of large model platform that integrates computing power, operational management, and application development. The experts demonstrated how LLM is already improving workflows across research, advisory, and investment banking services, both internally and with partners. The company is also exploring ways to enhance client services using intelligent tools across various business areas.

The session included real-world case studies across various asset classes, showing how its Credit Analysis Management System (CAMS) enables quantitative credit assessment, real-time risk tracking, credit bond pricing and regulatory empowerment. Huatai Securities started developing CAMS in 2017, combining extensive market data with quantitative models and AI. Today, as the backbone of Huatai’s credit research ecosystem, it is widely used in credit risk management, trading, and investment research, and has strong potential for application in investment banking and asset management.

In response to evolving FICC market dynamics, the company has upgraded its Global FICC Electronic Trading Platform (HEADS) to manage strategy development, trade execution, and risk assessment across all asset classes in both domestic and international markets, including exchange-traded and over-the-counter products, connecting research to trading in a seamless process. Looking ahead, HEADS will strengthen its capabilities in overseas FICC trading, investment, and risk management, leveraging AI to create new products and build an integrated client service system.

This year marks Huatai Securities’ 10th anniversary of listing on the Hong Kong Stock Exchange, a milestone that accelerated the company’s international expansion. The company now runs a connected financial network across Mainland China, Hong Kong, the US, the UK, Singapore, and other regions, with technology supporting both local and international business. As it grows globally, Huatai is building stronger technology capabilities to empower business growth, using its platforms to connect assets, clients, and products while expanding its global presence.

Hashtag: #huataisecurities

The issuer is solely responsible for the content of this announcement.

About Huatai Securities

Incorporated in April 1991, Huatai Securities is a leading technology-driven securities group in China, with a highly collaborative business model, a cutting-edge digital platform and an extensive and engaging customer base. It provides comprehensive financial services to individual and institutional clients, including wealth management, investment banking, sales and trading, investment management, among others, with a substantial international presence.

Telix Appoints Paul Schaffer as Chief Technology Officer

MELBOURNE, Australia and INDIANAPOLIS, April 7, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that is has appointed Dr. Paul Schaffer to the newly created role of Chief Technology Officer (CTO), effective today.  

Dr. Schaffer has been CTO at ARTMS Inc. (ARTMS) (acquired by Telix in 2024) for the past seven years, as well as Director, Life Science at TRIUMF, Canada’s particle accelerator research centre, since 2012. Based in Vancouver, Canada, Dr. Schaffer is widely recognized for his role in the buildout and transformation of the TRIUMF Life Sciences program, which included design and construction of a major multi-cyclotron radiochemistry facility and the development of the ARTMS QUANTM Irradiation System® (QIS®) for large-scale isotope production, which was commercialized and later acquired by Telix.

As Telix CTO, Dr. Schaffer will be responsible for harnessing the power of technology to advance Telix’s capabilities in radiopharmaceutical research, development, and clinical applications. Dr. Schaffer will cover areas including chemistry, physics, artificial intelligence (AI), dosimetry, and data analytics, complementing the work of Telix’s Chief Scientist, Dr. Michael Wheatcroft, and his team in driving cutting-edge research and development (R&D).

Dr. Schaffer said, “I’m excited to be taking on this role at such a pivotal time for Telix, as the Company advances rapidly toward its mission of transforming patient care. Telix has a bold commitment to innovation, and I’m thrilled to collaborate with this talented team to help drive R&D for the technologies behind the next generation of radiotherapeutics.”

Dr. Christian Behrenbruch, Telix Managing Director and Group Chief Executive Office, said, “Paul has an impressive track record of driving innovation in life sciences technology, including his groundbreaking work in large-scale isotope production. I have first-hand experience of Paul’s impressive intellect, ideas and passion through his work at TRIUMF and with ARTMS, so it is a great pleasure to have him join the broader Telix team as we continue to lead radiopharmaceutical innovation.”

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. ARTMS, IsoTherapeutics, Lightpoint, Optimal Tracers and RLS are Telix Group companies. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedInX and Facebook.

Telix Investor Relations
Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

Legal Notices

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

©2025 Telix Pharmaceuticals Limited. Telix Pharmaceuticals®, Telix Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Trademark registration status may vary from country to country.